ArticleRadiology case reports2025
A rare case of recurrent adenoid cystic carcinoma of the breast with weak hormone receptor positivity.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary adenoid cystic carcinoma of the breast: a clinicopathological case series.Korean journal of clinical oncology · 2026Article
- Beyond its Rarity: A 10-year Study on Primary Adenoid Cystic Carcinoma of the Breast from a Tertiary Care Center.Journal of mid-life healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid cystic carcinoma (ACC) of the breast is an exceptionally rare malignancy, accounting for less than 0.1% of all breast cancers. Despite its favorable prognosis, optimal management remains undefined due to its rarity and lack of consensus guidelines. We report a case of recurrent ACC of the breast, illustrating treatment challenges and the need for individualized management. A 64-year-old woman presented with a palpable mass in her left breast; imaging and biopsy confirmed ACC with very poor hormone receptor positivity. She started neoadjuvant chemotherapy but discontinued after 3 cycles due to severe neutropenia and lack of response. She then underwent breast-conserving surgery and radiotherapy. Three years later, she developed a local recurrence. Imaging and biopsy reconfirmed ACC and a subsequent total mastectomy achieved clear margins. Local recurrence of breast ACC can occur despite chemotherapy, surgery, and radiotherapy. Ineffectiveness of chemotherapy and recurrence after breast-conserving surgery suggest mastectomy might offer better local control. Hormone receptor positivity raises considerations for hormonal therapy, not standard for typically triple-negative ACC. The rarity of ACC complicates establishing standard protocols, necessitating personalized treatment plans based on tumor and patient factors. Recurrent breast ACC presents management challenges due to rarity and unpredictable behavior. More aggressive surgery and tailored treatment may improve outcomes. Further research is essential to develop evidence-based guidelines for managing this rare carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.